Antimetabolites, Antineoplastic

• 

  Subject Areas on Research

  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. 
  • 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 
  • 5-Azacitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-Dose Chemotherapy. 
  • 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. 
  • A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. 
  • A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. 
  • A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). 
  • A challenge to the therapeutic nihilism of ESPAC-1. 
  • A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. 
  • A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. 
  • A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. 
  • A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. 
  • A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. 
  • A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. 
  • Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. 
  • Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant therapy for surgically resected pancreatic adenocarcinoma. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. 
  • An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 
  • Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. 
  • Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. 
  • Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. 
  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. 
  • Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. 
  • Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Chemoradiation for localized pancreatic cancer: another perspective. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia. 
  • Chromosomes with high gene density are preferentially repaired in human cells. 
  • Chronic myelogenous leukemia. 
  • Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. 
  • Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. 
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. 
  • Comparison of cytostatic sensitivities of L 1210 cells and human stimulated lymphocytes in three cell proliferation assays. 
  • Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. 
  • Complete pathologic response after chemoradiation for rectal cancer. 
  • Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. 
  • Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. 
  • Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. 
  • Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. 
  • Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. 
  • DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. 
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 
  • Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. 
  • Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients. 
  • Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). 
  • Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. 
  • Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. 
  • Erbium:YAG laser pretreatment accelerates the response of Bowen's disease treated by topical 5-fluorouracil. 
  • Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series. 
  • Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. 
  • F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia. 
  • Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. 
  • Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. 
  • Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. 
  • Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. 
  • Gemcitabine in the management of metastatic breast cancer: a systematic review. 
  • Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. 
  • Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. 
  • Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. 
  • High-dose methotrexate for primary CNS lymphoma in the elderly. 
  • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. 
  • Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. 
  • Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. 
  • Lung transplantation: advances in immunosuppression. 
  • Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. 
  • Measuring the severity of topical 5-fluorouracil toxicity. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. 
  • Methotrexate treatment for sarcoid-associated panuveitis. 
  • Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer. 
  • Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. 
  • New applications of gemcitabine and future directions in the management of pancreatic cancer. 
  • Novel therapeutic targets of tumor metabolism. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. 
  • Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. 
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. 
  • Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. 
  • Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. 
  • Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. 
  • PET concerns in bevacizumab treatment. 
  • Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. 
  • Pancreatic cancer: translating lessons from mouse models. 
  • Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. 
  • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. 
  • Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. 
  • PharmGKB summary: methotrexate pathway. 
  • Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. 
  • Phase I studies with the novel nucleoside analog gemcitabine. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. 
  • Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. 
  • Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. 
  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. 
  • Phase II study of gemcitabine in advanced colorectal adenocarcinoma. 
  • Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. 
  • Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. 
  • Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. 
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. 
  • Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. 
  • Preoperative radiotherapy for rectal cancer: benefits and controversies. 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Progressive outer retinal necrosis. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. 
  • Protein, fat, and carbohydrate requirements during starvation: anaplerosis and cataplerosis. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. 
  • Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. 
  • Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. 
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 
  • Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. 
  • Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 
  • Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. 
  • Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. 
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. 
  • Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. 
  • Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 
  • Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. 
  • Seesaw nystagmus following whole brain irradiation and intrathecal methotrexate. 
  • Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate. 
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. 
  • Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. 
  • Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. 
  • Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. 
  • T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. 
  • TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 
  • Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow. 
  • The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. 
  • The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. 
  • Trabeculectomy with intraoperative 5-fluorouracil. 
  • Transport properties of pancreatic cancer describe gemcitabine delivery and response. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. 
  • Where there's smoke, is there fire? 
• 

  Keywords of People

  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics